Clinical trial
Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human)…
NCT00066989 · Nabi Biopharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00066989 |
|---|---|
| Title | Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates |
| Official title | A Double Blind, Randomized, Multicenter Stratified Study to Assess the Safety of an Intravenous Staphylococcus Aureus Immune Globulin (Human) [Altastaph] in Low-Birth-Weight-Neonates |
| Lead sponsor | Nabi Biopharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Staphylococcal Infections |
| Intervention type | Drug |
| Interventions | Staphylococcus aureus Immune Globulin (Human) 5% |
| Enrollment | 200 |
| Start date | Jul 1, 2003 |
| Primary completion | Aug 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | Aug 11, 2003 |
| Last update posted | May 14, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: